|  |  |
| --- | --- |
|  | |
| Journal Name: | [**Advances in Research**](https://journalair.com/index.php/AIR) |
| Manuscript Number: | **Ms\_AIR\_141917** |
| Title of the Manuscript: | **Clinical and Cutaneous Manifestations of Leprosy: A Systematic Review with Emphasis on Early Diagnosis and Integrated Approach** |
| Type of the Article | Review article |

|  |  |  |
| --- | --- | --- |
| PART 1: Comments | | |
|  | Reviewer’s comment **Artificial Intelligence (AI) generated or assisted review comments are strictly prohibited during peer review.** | **Author’s Feedback** (It is mandatory that authors should write his/her feedback here) |
| **Please write a few sentences regarding the importance of this manuscript for the scientific community. A minimum of 3-4 sentences may be required for this part.** | This study highlights the diverse clinical and cutaneous manifestation of the disease.  The integrated approach emphasised in the review is crucial for effective treatment.  Valuable resource for healthcare professionals.  This work has potential to enhance clinical practice and inform public health strategies for leprosy control. |  |
| **Is the title of the article suitable?**  **(If not please suggest an alternative title)** | yes it is  Suggestion- Unveiling Leprosy: systemic review of clinical and cutaneous manifestations. |  |
| Is the abstract of the article comprehensive? Do you suggest the addition (or deletion) of some points in this section? Please write your suggestions here. | it is appropriate. |  |
| Is the manuscript scientifically, correct? Please write here. | yes |  |
| **Are the references sufficient and recent? If you have suggestions of additional references, please mention them in the review form.** | no, enough study has been included |  |
| Is the language/English quality of the article suitable for scholarly communications? | yes. |  |
| Optional/General comments | few sentences are on repeat in discussion and conclusion that can be edited.  In introduction and discussion we can write about relapse, reinfection and resistant cases, about how they pose challenges in the both curing and preventing the disease.  Mentioning any programs or Apps initiated by government for early case detection, preventing drop outs. |  |

|  |  |  |
| --- | --- | --- |
| **PART 2:** | | |
|  | **Reviewer’s comment** | **Author’s comment** *(if agreed with reviewer, correct the manuscript and highlight that part in the manuscript. It is mandatory that authors should write his/her feedback here)* |
| **Are there ethical issues in this manuscript?** | *(If yes, Kindly please write down the ethical issues here in details)* |  |

**Reviewer details:**

**Divya Yadav, India**